These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 38279230)

  • 21. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.
    Saykin AJ; Shen L; Yao X; Kim S; Nho K; Risacher SL; Ramanan VK; Foroud TM; Faber KM; Sarwar N; Munsie LM; Hu X; Soares HD; Potkin SG; Thompson PM; Kauwe JS; Kaddurah-Daouk R; Green RC; Toga AW; Weiner MW;
    Alzheimers Dement; 2015 Jul; 11(7):792-814. PubMed ID: 26194313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities.
    Reitz C
    Expert Rev Mol Diagn; 2015 Mar; 15(3):339-48. PubMed ID: 25634383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
    Hayes JP; Logue MW; Sadeh N; Spielberg JM; Verfaellie M; Hayes SM; Reagan A; Salat DH; Wolf EJ; McGlinchey RE; Milberg WP; Stone A; Schichman SA; Miller MW
    Brain; 2017 Mar; 140(3):813-825. PubMed ID: 28077398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study.
    Ware EB; Faul JD; Mitchell CM; Bakulski KM
    BMC Med Genomics; 2020 Nov; 13(1):164. PubMed ID: 33143703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
    Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
    Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease.
    Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM
    J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
    Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M
    J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
    Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.
    de Mauléon A; Soto M; Kiyasova V; Delrieu J; Guignot I; Galtier S; Lilamand M; Cantet C; Lala F; Sastre N; Andrieu S; Pueyo M; Ousset PJ; Vellas B
    J Prev Alzheimers Dis; 2017; 4(3):183-193. PubMed ID: 29182709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphocytes, Platelets, Erythrocytes, and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis.
    Pluta R; Ułamek-Kozioł M
    Adv Exp Med Biol; 2019; 1118():71-82. PubMed ID: 30747418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic overlap between Alzheimer's disease and blood lipid levels.
    van der Linden RJ; Reus LM; De Witte W; Tijms BM; Olde Rikkert M; Visser PJ; Poelmans G
    Neurobiol Aging; 2021 Dec; 108():189-195. PubMed ID: 34340865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.
    Wightman DP; Jansen IE; Savage JE; Shadrin AA; Bahrami S; Holland D; Rongve A; Børte S; Winsvold BS; Drange OK; Martinsen AE; Skogholt AH; Willer C; Bråthen G; Bosnes I; Nielsen JB; Fritsche LG; Thomas LF; Pedersen LM; Gabrielsen ME; Johnsen MB; Meisingset TW; Zhou W; Proitsi P; Hodges A; Dobson R; Velayudhan L; Heilbron K; Auton A; ; Sealock JM; Davis LK; Pedersen NL; Reynolds CA; Karlsson IK; Magnusson S; Stefansson H; Thordardottir S; Jonsson PV; Snaedal J; Zettergren A; Skoog I; Kern S; Waern M; Zetterberg H; Blennow K; Stordal E; Hveem K; Zwart JA; Athanasiu L; Selnes P; Saltvedt I; Sando SB; Ulstein I; Djurovic S; Fladby T; Aarsland D; Selbæk G; Ripke S; Stefansson K; Andreassen OA; Posthuma D
    Nat Genet; 2021 Sep; 53(9):1276-1282. PubMed ID: 34493870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first case series of Chinese patients in Hong Kong with familial Alzheimer's disease compared with those with biomarker-confirmed sporadic late-onset Alzheimer's disease.
    Shea YF; Chu LW; Lee SC; Chan AO
    Hong Kong Med J; 2017 Dec; 23(6):579-85. PubMed ID: 29123074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrative-omics for discovery of network-level disease biomarkers: a case study in Alzheimer's disease.
    Xie L; He B; Varathan P; Nho K; Risacher SL; Saykin AJ; Salama P; Yan J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33971669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomics of Alzheimer's disease: Value of high-throughput genomic technologies to dissect its etiology.
    Tosto G; Reitz C
    Mol Cell Probes; 2016 Dec; 30(6):397-403. PubMed ID: 27618776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers in Sporadic and Familial Alzheimer's Disease.
    Lista S; O'Bryant SE; Blennow K; Dubois B; Hugon J; Zetterberg H; Hampel H
    J Alzheimers Dis; 2015; 47(2):291-317. PubMed ID: 26401553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma biomarkers for Alzheimer's disease: much needed but tough to find.
    Bazenet C; Lovestone S
    Biomark Med; 2012 Aug; 6(4):441-54. PubMed ID: 22917146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.